The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

Regular physical activity reduces the risk of chronic obstructive pulmonary disease (COPD)1 and improves the prognosis in affected patients.2 In contrast, ambient air pollution, is a substantial risk ...

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Dr. Ross Camidge has helped treat thousands of lung cancer patients. Now, in a crazy life twist, Camidge is a lung cancer patient himself.

Topline data were announced from a phase 3 trial evaluating efzofitimod in patients with pulmonary sarcoidosis.

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...

GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society Congress 2025: London, UK Wednesday, September 17, 2025, 11:00 Hrs [IST] GSK ...

Privately-held Areteia Therapeutics has announced positive results from the Phase III EXHALE-4 efficacy and safety study of ...

For a long time, physicians and scientists believed our lungs were sterile (germ-free). But modern science indicates ...

Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.